PR Newswire BiotechOriginal article
Datos de fase III de olatorepatida --agonista dual sesgado de GLP-1/GIP de Hansoh-- presentados en la EASD
Data ReadoutpositiveolatorepatidaPositive
AI Analysis
Summary
Hansoh presented Phase 3 data for olatorepatida, a dual GLP-1/GIP agonist, showing 19.3% weight loss at week 48 at the EASD conference in Milan.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
19.3% weight loss at week 48
Importance:7/10
Sentiment:
0.70
Phase 3 dataweight lossGLP-1/GIP agonistEASD conferencepositive data
Related Companies
Read the original article
Published by PR Newswire Biotech on October 2, 2026 12:41 PM